Cancer Immunotherapies

lt;p>Priya Hays, Ph.D. is an accomplished science writer, having written and published three books. Her latest book Advancing Healthcare Through Personalized Medicine is a monograph on the implementation of the latest advances in precision medicine, with a second edition due out soon. She has authored over fifteen publications in journals as varied as the Bulletin of Science, Technology and Society, L'Esprit Createur, Interdisciplinary Literary Studies, Genetics in Medicine, Journal of Clinical Investigation and Studies and collaboration on adverse effects of CAR T-cell therapy with two physicians from the University of California, San Diego Health System in Future Oncology. She is an elected member of the American Society of Clinical Oncology, American College of Medical Genetics and Genomics, and the Society for Immunotherapy of Cancer. She has an A.B. with Honors from Dartmouth College in Biochemistry and Comparative Literature, an M.S. in Genetics from the University of California, Davis, and a Ph.D. in Literature from the University of California, San Diego.

Development of Cancer Immunotherapies.- Melanoma.- Engaging pattern recognition receptors in solid tumors to generate systemic anti-tumor immunity.- Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer.- Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.- Lag3: From Bench to Bedside.- Immunotherapy in Genitourinary Malignancy: evolution in revolution or revolution in evolution.- Immune-based therapeutic interventions for Acute Myeloid Leukemia.-Off-the-shelf chimeric antigen receptor immune cells from human pluripotent stem cells.- The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cells.- Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematological Malignancies.